BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18650843)

  • 1. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia.
    Lagadinou ED; Ziros PG; Tsopra OA; Dimas K; Kokkinou D; Thanopoulou E; Karakantza M; Pantazis P; Spyridonidis A; Zoumbos NC
    Leukemia; 2008 Oct; 22(10):1899-908. PubMed ID: 18650843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation.
    Cripe LD; Gelfanov VM; Smith EA; Spigel DR; Phillips CA; Gabig TG; Jung SH; Fyffe J; Hartman AD; Kneebone P; Mercola D; Burgess GS; Boswell HS
    Leukemia; 2002 May; 16(5):799-812. PubMed ID: 11986940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidation-triggered c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase pathways for apoptosis in human leukaemic cells stimulated by epigallocatechin-3-gallate (EGCG): a distinct pathway from those of chemically induced and receptor-mediated apoptosis.
    Saeki K; Kobayashi N; Inazawa Y; Zhang H; Nishitoh H; Ichijo H; Saeki K; Isemura M; Yuo A
    Biochem J; 2002 Dec; 368(Pt 3):705-20. PubMed ID: 12206715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
    Rao AV; Valk PJ; Metzeler KH; Acharya CR; Tuchman SA; Stevenson MM; Rizzieri DA; Delwel R; Buske C; Bohlander SK; Potti A; Löwenberg B
    J Clin Oncol; 2009 Nov; 27(33):5580-6. PubMed ID: 19858393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells.
    Xu B; Shi P; Fombon IS; Zhang Y; Huang F; Wang W; Zhou S
    Blood Cells Mol Dis; 2011 Dec; 47(4):264-9. PubMed ID: 21911303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.
    Côme MG; Skladanowski A; Larsen AK; Laurent G
    Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
    Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
    Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
    Yang GS; Minden MD; McCulloch EA
    Leukemia; 1994 Dec; 8(12):2065-75. PubMed ID: 7807996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive oxygen species activate differentiation gene transcription of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway.
    Lam CF; Yeung HT; Lam YM; Ng RK
    Leuk Res; 2018 May; 68():112-119. PubMed ID: 29609096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
    Faderl S; Estrov Z; Kantarjian HM; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski JM; Priebe W
    Anticancer Res; 2001; 21(6A):3777-84. PubMed ID: 11911247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
    Qiu L; Zhou G; Cao S
    Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
    Li F; Meng L; Zhou J; Xing H; Wang S; Xu G; Zhu H; Wang B; Chen G; Lu YP; Ma D
    Biochem Biophys Res Commun; 2005 Oct; 335(4):1070-7. PubMed ID: 16105650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.
    Kim JS; Eom JI; Cheong JW; Choi AJ; Lee JK; Yang WI; Min YH
    Clin Cancer Res; 2007 Feb; 13(3):1019-28. PubMed ID: 17289898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
    Choi CH; Ling V
    Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment outcome of multidrug resistance related mRNA expression and c-jun-N-terminal kinase activity in patients with acute myeloid leukemia].
    Do JH; Oh SH; Song EJ; Chung JS; Kang CD; Lee EY
    Korean J Lab Med; 2007 Aug; 27(4):229-36. PubMed ID: 18094581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
    Maha A; Cheong SK; Leong CF; Seow HF
    Malays J Pathol; 2009 Dec; 31(2):81-91. PubMed ID: 20514850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
    Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K
    Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1.
    Kajiguchi T; Yamamoto K; Hossain K; Akhand AA; Nakashima I; Naoe T; Saito H; Emi N
    Leukemia; 2003 Nov; 17(11):2189-95. PubMed ID: 12931215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.